Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di [177lu] lu-dotatato negli adulti con meningioma intracranico di grado 1-3 intracranico progressivo (MOMENTUM-1)

17 novembre 2026 aggiornato da: RTOG Foundation, Inc.

Momentum-1: uno studio multicentrico, randomizzato, in aperto, di fase II di [177lu] Lu-dotatato negli adulti con meningioma progressivo di grado 1-3 intracranico

This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.

Tipo di studio

Interventistico

Iscrizione (Stimato)

130

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • California
      • Irvine, California, Stati Uniti, 92697
        • Reclutamento
        • University of California, Irvine
        • Investigatore principale:
          • Daniela Bota, MD, PhD
        • Contatto:
      • La Jolla, California, Stati Uniti, 92093
        • Reclutamento
        • University of California San Diego - Moores Cancer Center
        • Investigatore principale:
          • Jona Hattangadi-Gluth, MD
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • USC Keck School of Medicine
        • Contatto:
        • Investigatore principale:
          • Aram Modrek, MD, PhD
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06520
        • Reclutamento
        • Yale University
        • Investigatore principale:
          • Sylvia Kurz, MD, PhD
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32207
        • Reclutamento
        • Baptist MD Anderson Cancer Center
        • Investigatore principale:
          • Michael Olson, MD PhD
        • Contatto:
        • Sub-investigatore:
          • Andre Alvarez, MD PhD
      • Miami, Florida, Stati Uniti, 33146
        • Reclutamento
        • University of Miami
        • Contatto:
        • Investigatore principale:
          • Marina Kushnirsky, MD
      • Miami, Florida, Stati Uniti, 33176
      • Tampa, Florida, Stati Uniti, 33543
        • Reclutamento
        • Moffitt Cancer Center
        • Contatto:
        • Investigatore principale:
          • Andre Luiz Beer Furlan, MD, PhD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30318
        • Reclutamento
        • Piedmont Healthcare
        • Contatto:
        • Investigatore principale:
          • Adam Nowlan, MD, MPH
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Reclutamento
        • Indiana University
        • Investigatore principale:
          • Kathryn Nevel, MD
        • Contatto:
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa Health Care
        • Contatto:
        • Investigatore principale:
          • Kristin Plichta, MD, PhD
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan Rogel Cancer Center
        • Contatto:
        • Investigatore principale:
          • Sean Miller, MD
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Hospital
        • Contatto:
        • Investigatore principale:
          • Tobias Walber, MD, PhD, MPH
    • New York
      • New York, New York, Stati Uniti, 10016
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 22708
        • Reclutamento
        • Duke University Medical Center
        • Investigatore principale:
          • Margaret Johnson, MD
        • Contatto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Thomas Jefferson University Hospital
        • Investigatore principale:
          • Iyad Alnahhas, MD
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • MD Anderson Cancer Center
        • Contatto:
        • Investigatore principale:
          • Carlos Kamiya-Matsuoka, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Medical College of Wisconsin
        • Contatto:
        • Investigatore principale:
          • Michael Straza, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

STEP 1 REGISTRATION

  • Aged >= 18 years
  • Histologically confirmed diagnosis of WHO grade 1-3 meningioma
  • Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
  • The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
  • Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
  • Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
  • ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
  • ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
  • Development of a new measurable lesion
  • The following scans must be available for submission for central radiology review:
  • Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
  • Progression gadolinium-enhanced MRI brain scan

STEP 2 REGISTRATION

  • Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
  • ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
  • ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
  • Development of a new measurable lesion.
  • [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
  • Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
  • Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
  • Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
  • Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelet count ≥ 75,000/mm3
  • Hemoglobin ≥ 8 g/dL
  • Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
  • AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
  • Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
  • Potassium within normal limits.

Exclusion Criteria:

  • Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
  • Patients with radiation-associated meningiomas.
  • Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
  • Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
  • Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
  • Patients requiring immediate local therapy (e.g. surgical resection).
  • Surgical procedure within the timeframes listed below, prior to step 2 registration.
  • 28 days from any prior craniotomy
  • 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
  • Treatment within the timeframes specified below, prior to step 2 registration.
  • 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
  • 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
  • A target lesion is excluded if it has received any of the following:
  • More than 2 total prior courses of radiation
  • More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
  • Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.

For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.

  • All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
  • Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
  • Active infection requiring current use of intravenous therapy with antibiotics.
  • Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
  • An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
  • Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: [177Lu]Lu-DOTATATE

Study participants receive [177Lu]Lu-DOTATATE

The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).

Altri nomi:
  • Lutathera
Altro: Control

Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression

Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.

Altri nomi:
  • Avastin (bevacizumab), Afinitor (everolimus), Sutent (sunitinib)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression Free Survival (PFS)
Lasso di tempo: Assessed up to 4 years

Proportion of patients alive without disease progression per current RANO meningioma criteria

Assessed up to 4 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression free survival at 6 months (PFS-6)
Lasso di tempo: 6 months

Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria

6 months
Overall Survival at 12 months (OS-12)
Lasso di tempo: 12 months

Proportion of participants alive at 12 months

12 months
Overall survival (OS)
Lasso di tempo: Assessed up to 4 years

Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria

Assessed up to 4 years
Progression-free Survival after cross-over (PFS2)
Lasso di tempo: Assessed up to 4 years

Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first.

Assessed up to 4 years
Disease Control Rate (DCR)
Lasso di tempo: Assessed up to 4 years

Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria

Assessed up to 4 years
Objective response rate (ORR)
Lasso di tempo: Assessed up to 4 years

Proportion of patients achieving complete or partial response as per RANO meningioma criteria.

Assessed up to 4 years
Number of participants by highest grade treatment-emergent adverse event (TEAE):
Lasso di tempo: Assessed up to 4 years

Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event).

Assessed up to 4 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Sylvia C Kurz, MD, PhD, Yale University
  • Investigatore principale: Erik P Sulman, MD,PhD, Duke University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

24 agosto 2025

Completamento primario (Stimato)

1 agosto 2029

Completamento dello studio (Stimato)

1 agosto 2030

Date di iscrizione allo studio

Primo inviato

22 aprile 2025

Primo inviato che soddisfa i criteri di controllo qualità

30 aprile 2025

Primo Inserito (Effettivo)

2 maggio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .